Stock Code: 300497 Stock Abbreviation: Fuxiang Shares Announcement No.: 2026-066
Jiangxi Fuxiang Pharmaceutical Co., Ltd.
Announcement of Resolutions of the 10th Meeting of the 5th Board of Directors
The Company and all members of the Board of Directors guarantee the content of the information disclosure is true, accurate, and complete, and that there are no false records, misleading statements, or major omissions.
I. Convening of the Board of Directors Meeting
The 10th meeting of the 5th Board of Directors of Jiangxi Fuxiang Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") was notified to all directors via email on July 29, 2026, and was held on July 31, 2026, in the form of on-site and remote communication at the third-floor conference room of the Company's premises at No. 2, Yuli Industrial Zone, Changjiang District, Jingdezhen City.
Seven directors were eligible to attend, and seven directors actually attended. Directors JIZU JOHN CHENG (Mr. Cheng Jianzu), Mr. Li Huiyue, Mr. Liu Hong, Mr. Chen Xiangqiang, and Ms. Ji Xiaoqing attended the meeting via written voting. The meeting was chaired by Chairman Bao Jianhua, and senior management of the Company attended the meeting as non-voting participants. The convening and voting procedures of the meeting comply with the relevant provisions of the "Company Law of the People's Republic of China" and other laws and regulations, as well as the Company's Articles of Association, and are legal and valid.
II. Deliberation of the Board of Directors Meeting
After deliberation by the attending directors, the following resolutions were passed:
1. Deliberation and Approval of the Proposal on the Company Meeting the Conditions for Issuing Shares to Specific Targets
In accordance with the "Company Law of the People's Republic of China," the "Securities Law of the People's Republic of China," the "Administrative Measures for the Issuance and Registration of Securities by Listed Companies," and other relevant laws, regulations, and normative documents, and combined with the Company's actual situation, the Company's Board of Directors has conducted a thorough item-by-item review and argumentation. It is believed that the Company meets the requirements and conditions for issuing shares to specific targets on the ChiNext market as stipulated by current laws, regulations, and normative documents, and possesses the qualifications and conditions for issuing shares to specific targets.
The specific content can be found in the announcement published by the Company on the information disclosure website of the ChiNext market designated by the China Securities Regulatory Commission (hereinafter referred to as the "CSRC"), Giant Information Network (www.cninfo.com.cn).
The Company's Board Strategy Committee, Independent Directors' Special Committee, and Board Audit Committee have reviewed and approved this proposal.
Voting Result: 7 votes in favor, 0 votes against, 0 abstentions.
This proposal still needs to be submitted to the Company's general meeting of shareholders for deliberation.
2. Deliberation and Approval of the Proposal on the Company's 2026 Plan for Issuing Shares to Specific Targets
The specific plan for the Company's 2026 issuance of shares to specific targets (hereinafter referred to as the "Current Issuance") is as follows:
2.1. Type and Par Value of Shares to be Issued
The shares to be issued are RMB ordinary shares (A shares) listed in China, with a par value of RMB 1.00 per share.
2.2. Issuance Method and Timing
The Current Issuance will be conducted through the issuance of RMB ordinary shares to specific targets. After the application for the Current Issuance is reviewed and approved by the Shenzhen Stock Exchange (hereinafter referred to as the "SZSE") and registered with the CSRC, the Company will select an appropriate time to issue shares to specific targets within the prescribed validity period.